Lisa Johnson, CEO of BioForward Wisconsin, on Building a Biohealth Ecosystem and What Comes Next

What does it take to build a biohealth ecosystem that can compete nationally? In this episode of BioTalk, Lisa Johnson, CEO of BioForward Wisconsin, discusses how Wisconsin helped shape the early use of the term "biohealth" and how that approach has supported the growth of its life sciences sector. Lisa shares how BioForward connects industry, academia, and government to strengthen the state's ecosystem, along with key developments that have brought increased attention to the region, including the expansion of Eli Lilly and Company. She also reflects on Wisconsin's designation as a Biohealth Tech Hub through the U.S. Economic Development Administration and what it means for future growth. The conversation highlights both momentum and ongoing challenges, particularly around access to early-stage capital and building a stronger pipeline of companies. Lisa outlines what will be required for Wisconsin to continue growing as a competitive biohealth hub. Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Lisa Johnson is the Chief Executive Officer of BioForward Wisconsin, the state's member-driven biohealth industry association dedicated to advancing Wisconsin as a global leader in biohealth innovation. In her role, she leads efforts to strengthen the state's ecosystem by connecting industry, academia, and government partners to support company growth, workforce development, and investment attraction. Lisa brings extensive experience in economic development, public policy, and industry leadership, with a focus on building collaborative environments that drive regional competitiveness. She has been instrumental in positioning Wisconsin as a recognized biohealth hub, including leading the state's successful designation as a Biohealth Tech Hub through the U.S. Economic Development Administration. Through her work, she continues to champion initiatives that support emerging companies, expand access to capital, and foster long-term growth across the biohealth sector.